CA2253078C - Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones - Google Patents

Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones Download PDF

Info

Publication number: CA2253078C
Authority: CA; Canada
Prior art keywords: myelin; fragments; complement; antibodies; composition
Prior art date: 1997-10-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2253078

Other languages

English (en)

Other versions

CA2253078A1 (fr

Inventor

John D. Steeves

Jason K. Dyer

Hans S. Keirstead

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of British Columbia

Original Assignee

University of British Columbia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-28

Filing date

1998-10-28

Publication date

2001-05-01

1997-10-28 Priority claimed from CA 2219683 external-priority patent/CA2219683A1/fr

1998-10-28 Application filed by University of British Columbia filed Critical University of British Columbia

1998-10-28 Priority to CA 2253078 priority Critical patent/CA2253078C/fr

1999-04-28 Publication of CA2253078A1 publication Critical patent/CA2253078A1/fr

2001-05-01 Application granted granted Critical

2001-05-01 Publication of CA2253078C publication Critical patent/CA2253078C/fr

2018-10-28 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

102000006386 Myelin Proteins Human genes 0.000 title claims abstract description 144
108010083674 Myelin Proteins Proteins 0.000 title claims abstract description 144
210000005012 myelin Anatomy 0.000 title claims abstract description 144
239000000203 mixture Substances 0.000 title claims abstract description 71
210000003169 central nervous system Anatomy 0.000 title claims description 60
238000000034 method Methods 0.000 title abstract description 56
230000001900 immune effect Effects 0.000 title description 41
230000009689 neuronal regeneration Effects 0.000 title description 2
210000002569 neuron Anatomy 0.000 claims abstract description 92
230000008929 regeneration Effects 0.000 claims abstract description 66
238000011069 regeneration method Methods 0.000 claims abstract description 66
108010069112 Complement System Proteins Proteins 0.000 claims abstract description 33
102000000989 Complement System Proteins Human genes 0.000 claims abstract description 33
230000008439 repair process Effects 0.000 claims abstract description 21
230000001737 promoting effect Effects 0.000 claims abstract description 9
239000012634 fragment Substances 0.000 claims description 75
230000006378 damage Effects 0.000 claims description 56
210000004027 cell Anatomy 0.000 claims description 46
208000016192 Demyelinating disease Diseases 0.000 claims description 45
206010012305 Demyelination Diseases 0.000 claims description 45
208000014674 injury Diseases 0.000 claims description 44
208000027418 Wounds and injury Diseases 0.000 claims description 39
230000001052 transient effect Effects 0.000 claims description 34
238000011282 treatment Methods 0.000 claims description 27
230000027455 binding Effects 0.000 claims description 18
LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 claims description 16
239000003102 growth factor Substances 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 15
-1 NI220 Proteins 0.000 claims description 12
230000012010 growth Effects 0.000 claims description 12
108090000765 processed proteins & peptides Proteins 0.000 claims description 11
241000894007 species Species 0.000 claims description 11
102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 10
108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 10
102000017099 Myelin-Associated Glycoprotein Human genes 0.000 claims description 9
108010013731 Myelin-Associated Glycoprotein Proteins 0.000 claims description 9
108010025020 Nerve Growth Factor Proteins 0.000 claims description 9
102000007072 Nerve Growth Factors Human genes 0.000 claims description 9
108010077641 Nogo Proteins Proteins 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
208000020431 spinal cord injury Diseases 0.000 claims description 9
210000003007 myelin sheath Anatomy 0.000 claims description 8
201000010099 disease Diseases 0.000 claims description 7
238000001727 in vivo Methods 0.000 claims description 7
230000001684 chronic effect Effects 0.000 claims description 6
102000010410 Nogo Proteins Human genes 0.000 claims description 5
230000006764 neuronal dysfunction Effects 0.000 claims description 5
102100029831 Reticulon-4 Human genes 0.000 claims description 4
230000015572 biosynthetic process Effects 0.000 claims description 4
238000002560 therapeutic procedure Methods 0.000 claims description 4
230000008733 trauma Effects 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 3
102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 3
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims description 3
208000018737 Parkinson disease Diseases 0.000 claims description 3
238000001514 detection method Methods 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
238000011065 in-situ storage Methods 0.000 claims description 3
238000012544 monitoring process Methods 0.000 claims description 3
239000003900 neurotrophic factor Substances 0.000 claims description 3
230000003210 demyelinating effect Effects 0.000 claims description 2
210000002966 serum Anatomy 0.000 abstract description 44
230000009693 chronic damage Effects 0.000 abstract description 3
241001465754 Metazoa Species 0.000 description 85
230000000295 complement effect Effects 0.000 description 78
210000000278 spinal cord Anatomy 0.000 description 61
230000003902 lesion Effects 0.000 description 49
238000001802 infusion Methods 0.000 description 41
210000000463 red nucleus Anatomy 0.000 description 40
210000003050 axon Anatomy 0.000 description 36
210000001519 tissue Anatomy 0.000 description 35
238000002372 labelling Methods 0.000 description 33
DVGHHMFBFOTGLM-UHFFFAOYSA-L fluorogold Chemical compound F[Au][Au]F DVGHHMFBFOTGLM-UHFFFAOYSA-L 0.000 description 27
230000003376 axonal effect Effects 0.000 description 24
241000700159 Rattus Species 0.000 description 22
238000009792 diffusion process Methods 0.000 description 22
239000002953 phosphate buffered saline Substances 0.000 description 22
235000018102 proteins Nutrition 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
108090000623 proteins and genes Proteins 0.000 description 22
238000002347 injection Methods 0.000 description 19
239000007924 injection Substances 0.000 description 19
210000004556 brain Anatomy 0.000 description 18
210000000115 thoracic cavity Anatomy 0.000 description 17
230000001537 neural effect Effects 0.000 description 15
230000003204 osmotic effect Effects 0.000 description 15
239000000700 radioactive tracer Substances 0.000 description 15
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 14
230000037361 pathway Effects 0.000 description 14
230000000694 effects Effects 0.000 description 11
210000004248 oligodendroglia Anatomy 0.000 description 11
230000000926 neurological effect Effects 0.000 description 10
230000001172 regenerating effect Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 9
230000004154 complement system Effects 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
229960003299 ketamine Drugs 0.000 description 9
230000008569 process Effects 0.000 description 9
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 9
229960001600 xylazine Drugs 0.000 description 9
102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 8
108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 8
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 8
210000000133 brain stem Anatomy 0.000 description 8
210000002540 macrophage Anatomy 0.000 description 8
210000000274 microglia Anatomy 0.000 description 8
238000011084 recovery Methods 0.000 description 8
230000001629 suppression Effects 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
230000004913 activation Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000004927 fusion Effects 0.000 description 7
230000003447 ipsilateral effect Effects 0.000 description 7
239000000463 material Substances 0.000 description 7
230000004083 survival effect Effects 0.000 description 7
241000700199 Cavia porcellus Species 0.000 description 6
108010034753 Complement Membrane Attack Complex Proteins 0.000 description 6
229920002307 Dextran Polymers 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
210000003719 b-lymphocyte Anatomy 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
239000000834 fixative Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
210000000653 nervous system Anatomy 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
238000001356 surgical procedure Methods 0.000 description 6
241000271566 Aves Species 0.000 description 5
102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
241000251539 Vertebrata <Metazoa> Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000000427 antigen Substances 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
230000024203 complement activation Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
210000004884 grey matter Anatomy 0.000 description 5
230000002101 lytic effect Effects 0.000 description 5
210000001259 mesencephalon Anatomy 0.000 description 5
210000001428 peripheral nervous system Anatomy 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
230000001720 vestibular Effects 0.000 description 5
210000004885 white matter Anatomy 0.000 description 5
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
108020004511 Recombinant DNA Proteins 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
238000002684 laminectomy Methods 0.000 description 4
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
229910052753 mercury Inorganic materials 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
230000023105 myelination Effects 0.000 description 4
230000014207 opsonization Effects 0.000 description 4
238000012453 sprague-dawley rat model Methods 0.000 description 4
102000004506 Blood Proteins Human genes 0.000 description 3
108010017384 Blood Proteins Proteins 0.000 description 3
108060003951 Immunoglobulin Proteins 0.000 description 3
102000047918 Myelin Basic Human genes 0.000 description 3
101710107068 Myelin basic protein Proteins 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
235000013290 Sagittaria latifolia Nutrition 0.000 description 3
208000029224 Thoracic injury Diseases 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
210000001130 astrocyte Anatomy 0.000 description 3
210000003651 basophil Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000037396 body weight Effects 0.000 description 3
244000309464 bull Species 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
210000005056 cell body Anatomy 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
235000015246 common arrowhead Nutrition 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000001493 electron microscopy Methods 0.000 description 3
239000000835 fiber Substances 0.000 description 3
239000006260 foam Substances 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
230000003053 immunization Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
102000018358 immunoglobulin Human genes 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
210000004498 neuroglial cell Anatomy 0.000 description 3
230000007514 neuronal growth Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
210000000578 peripheral nerve Anatomy 0.000 description 3
210000004116 schwann cell Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000032258 transport Effects 0.000 description 3
210000001781 vestibular nucleus lateral Anatomy 0.000 description 3
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
206010011732 Cyst Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
241000235789 Hyperoartia Species 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108090000742 Neurotrophin 3 Proteins 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
235000014548 Rubus moluccanus Nutrition 0.000 description 2
208000020339 Spinal injury Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 2
102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
208000030886 Traumatic Brain injury Diseases 0.000 description 2
COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
239000012190 activator Substances 0.000 description 2
230000001800 adrenalinergic effect Effects 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000001413 amino acids Chemical group 0.000 description 2
230000001174 ascending effect Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
230000006931 brain damage Effects 0.000 description 2
231100000874 brain damage Toxicity 0.000 description 2
208000029028 brain injury Diseases 0.000 description 2
239000007978 cacodylate buffer Substances 0.000 description 2
230000015861 cell surface binding Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
230000002594 corticospinal effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
208000031513 cyst Diseases 0.000 description 2
210000001787 dendrite Anatomy 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
210000003979 eosinophil Anatomy 0.000 description 2
230000005284 excitation Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
230000012447 hatching Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
230000003137 locomotive effect Effects 0.000 description 2
210000005230 lumbar spinal cord Anatomy 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
239000003401 opiate antagonist Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000000242 pagocytic effect Effects 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
210000001176 projection neuron Anatomy 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
230000003016 quadriplegic effect Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000011514 reflex Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
150000003408 sphingolipids Chemical class 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
150000003445 sucroses Chemical class 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940034199 thyrotropin-releasing hormone Drugs 0.000 description 2
229950003937 tolonium Drugs 0.000 description 2
HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000009529 traumatic brain injury Effects 0.000 description 2
238000010246 ultrastructural analysis Methods 0.000 description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
206010003445 Ascites Diseases 0.000 description 1
KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZVGCGHVMJAECEG-UHFFFAOYSA-N Chinol Natural products COC1=C(O)C(C)=C(C)C(O)=C1OC ZVGCGHVMJAECEG-UHFFFAOYSA-N 0.000 description 1
108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
108010078015 Complement C3b Proteins 0.000 description 1
241000289427 Didelphidae Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
102400001368 Epidermal growth factor Human genes 0.000 description 1
101800003838 Epidermal growth factor Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000272496 Galliformes Species 0.000 description 1
102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
102100029268 Neurotrophin-3 Human genes 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
102000043276 Oncogene Human genes 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
206010033892 Paraplegia Diseases 0.000 description 1
206010034016 Paronychia Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000037169 Retrograde Degeneration Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000009471 action Effects 0.000 description 1
230000009692 acute damage Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
230000002491 angiogenic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000002502 anti-myelin effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
229960000794 baclofen Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000002469 basement membrane Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000035605 chemotaxis Effects 0.000 description 1
HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
108010052926 complement C3d,g Proteins 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000032798 delamination Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940116977 epidermal growth factor Drugs 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
210000000256 facial nerve Anatomy 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000001215 fluorescent labelling Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
230000008570 general process Effects 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
230000035876 healing Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000006749 inflammatory damage Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000019948 ion homeostasis Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
229950003188 isovaleryl diethylamide Drugs 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
239000003446 ligand Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000003622 mature neutrocyte Anatomy 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000007472 neurodevelopment Effects 0.000 description 1
230000007996 neuronal plasticity Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
238000002823 phage display Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
125000000405 phenylalanyl group Chemical group 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
210000001202 rhombencephalon Anatomy 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229920000260 silastic Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
229940032094 squalane Drugs 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
210000002330 subarachnoid space Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000008736 traumatic injury Effects 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
210000004440 vestibular nuclei Anatomy 0.000 description 1
230000021542 voluntary musculoskeletal movement Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Endocrinology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA 2253078 1997-10-28 1998-10-28 Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones Expired - Fee Related CA2253078C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA 2253078 CA2253078C (fr)	1997-10-28	1998-10-28	Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
CA2,219,683		1997-10-28
CA 2219683 CA2219683A1 (fr)	1997-10-28	1997-10-28	Composition immunologique et methodes d'utilisation pour perturber transitoirement la myelin au systeme nerveux central de mammiferes pour promouvoir la regeneration des neuronnes
CA2251410		1998-10-16
CA2,251,410		1998-10-16
CA 2253078 CA2253078C (fr)	1997-10-28	1998-10-28	Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones

Publications (2)

Publication Number	Publication Date
CA2253078A1 CA2253078A1 (fr)	1999-04-28
CA2253078C true CA2253078C (fr)	2001-05-01

Family

ID=27170505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2253078 Expired - Fee Related CA2253078C (fr)	1997-10-28	1998-10-28	Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones

Country Status (1)

Country	Link
CA (1)	CA2253078C (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10221390B2 (en)	2008-01-30	2019-03-05	Asterias Biotherapeutics, Inc.	Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050101014A1 (en)	2002-07-11	2005-05-12	Keirstead Hans S.	Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US7285415B2 (en)	2002-07-11	2007-10-23	The Regents Of The University Of California	Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
JP7482600B2 (ja) *	2015-11-20	2024-05-14	メモリアルスローンケタリングキャンサーセンター	血液脳脊髄液関門の透過性の調節

1998
- 1998-10-28 CA CA 2253078 patent/CA2253078C/fr not_active Expired - Fee Related

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10221390B2 (en)	2008-01-30	2019-03-05	Asterias Biotherapeutics, Inc.	Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells

Also Published As

Publication number	Publication date
CA2253078A1 (fr)	1999-04-28

Publication	Publication Date	Title
US7893029B2 (en)	2011-02-22	Recombinant lubricin molecules and uses thereof
US10494440B2 (en)	2019-12-03	Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
EP1047449B1 (fr)	2003-09-10	Compositions et procedes immunologiques utilises pour modifier provisoirement la myeline du systeme nerveux central des mammiferes afin de stimuler la regeneration neuronale
KR20180102116A (ko)	2018-09-14	항―ｃ―ＭＥＴ 항체 및 이의 용도
WO2021026074A1 (fr)	2021-02-11	Ciblage d'anticorps bispécifique de lymphocytes t régulateurs dans le traitement des états inflammatoires
CA2253078C (fr)	2001-05-01	Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones
US20050008641A1 (en)	2005-01-13	Composition for neuronal regeneration comprising myelin-specific antibodies and complement proteins
EP1173200A1 (fr)	2002-01-23	Composition pour la regeneration neuronale, comprenant des anticorps specifiques de la myeline et des complements
US11597765B2 (en)	2023-03-07	Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
CA2371592A1 (fr)	2000-11-02	Composition pour la regeneration neuronale, comprenant des anticorps specifiques de la myeline et des complements
US11702470B2 (en)	2023-07-18	Use of CXCL13 binding molecules to promote peripheral nerve regeneration
WO2006052660A9 (fr)	2006-08-31	Blocage du recepteur il-7 pour supprimer l'immunite
RU2773957C2 (ru)	2022-06-14	Модулятор активности
CA2219683A1 (fr)	1999-04-28	Composition immunologique et methodes d'utilisation pour perturber transitoirement la myelin au systeme nerveux central de mammiferes pour promouvoir la regeneration des neuronnes
CA2060384C (fr)	2001-06-12	Methode therapeutique
Keirstead	1994	Immunological suppression of central nervous system (CNS) myelin and the effect of myelin suppression on CNS repair after injury
JP2016519057A (ja)	2016-06-30	改変型ヒアルロナンおよびその癌の治療における使用

Legal Events

Date	Code	Title	Description
2000-03-14	EEER	Examination request
2013-12-10	MKLA	Lapsed	Effective date: 20131029

CA2253078C - Composition immunologique et sa methode d'utilisation pour provoquer une demyelinisation transitoire dans le systeme nerveux central d'un mammifere afin de favoriser la regeneration des neurones - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (1)

Applications Claiming Priority (5)

Publications (2)

Family

ID=27170505

Family Applications (1)

Country Status (1)

Cited By (1)

Families Citing this family (3)

Cited By (1)

Also Published As

Similar Documents

Legal Events